HIV-1 Vif promotes the G1- to S-phase cell-cycle transition

Blood

Volumn 117, Issue 4, 2011, Pages 1260-1269

  Wang, Jiangfang ^a   Reuschel, Emma L ^a   Shackelford, Jason M ^a   Jeang, Lauren ^a   Shivers, Debra K ^a   Diehl, J Alan ^a   Yu, Xiao Fang ^b   Finkel, Terri H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRD4; CULLLN5; CYCLIN DEPENDENT KINASE 9; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRAL INFECTIVITY FACTOR;

ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; HUMAN IMMUNODEFICIENCY VIRUS 1; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

EID: 79251560002     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-289215     Document Type: Article

References (49)

1. Malim MH, Emerman M. HIV-1 accessory proteins- ensuring viral survival in a hostile environment. Cell Host Microbe. 2008;3(6):388-398. (Pubitemid 351784365)
2. von Schwedler U, Song J, Aiken C, Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol. 1993;67(8):4945-4955. (Pubitemid 23215976)
3. Sova P, Volsky DJ. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol. 1993;67(10):6322-6326. (Pubitemid 23277551)
4. Simon JH, Malim MH. The human immunodeficiency virus type 1 Vif protein modulates the post-penetration stability of viral nucleoprotein complexes. J Virol. 1996;70(8):5297-5305.
5. Gabuzda DH, Lawrence K, Langhoff E, et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992;66(11):6489-6495.
6. Courcoul M, Patience C, Rey F, et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol. 1995;69(4):2068-2074.
7. Simon JH, Gaddis NC, Fouchier RA, Malim MH. Evidence for a newly discovered cellular anti- HIV-1 phenotype. Nat Med. 1998;4(12):1397-1400.
8. Madani N, Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol. 1998;72(12):10251-10255.
9. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418(6898):646-650.
10. Goh WC, Rogel ME, Kinsey CM, et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med. 1998;4(1):65-71.
11. Bartz SR, Rogel ME, Emerman M. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. J Virol. 1996;70(4):2324-2331.
12. Rogel ME, Wu LI, Emerman M. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol. 1995;69(2):882-888.
13. Re F, Braaten D, Franke EK, Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol. 1995;69(11):6859-6864.
14. Jowett JB, Planelles V, Poon B, Shah NP, Chen ML, Chen IS. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol. 1995;69(10):6304-6313.
15. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol. 1995;69(11):6705-6711.
16. Gummuluru S, Emerman M. Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J Virol. 1999;73(7):5422-5430.
17. Elder RT, Yu M, Chen M, Zhu X, Yanagida M, Zhao Y. HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. Virology. 2001;287(2):359-370.
18. Wang J, Shackelford JM, Selliah N, et al. The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell-cycle arrest. DNA Cell Biol. 2008;27(5):267-277. (Pubitemid 351655090)
19. Wang J, Shackelford JM, Casella CR, et al. The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology. 2007;359(2):243-252. (Pubitemid 46274864)
20. Sakai K, Dimas J, Lenardo MJ. The Vif and Vpr accessory proteins independently cause HIV-1- induced T cell cytopathicity and cell-cycle arrest. Proc Natl Acad Sci U S A. 2006;103(9):3369-3374. (Pubitemid 43346476)
21. DeHart JL, Bosque A, Harris RS, Planelles V. Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol. 2008;82(18):9265-9272.
22. Yu X, Yu Y, Liu B, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif- Cul5-SCF complex. Science. 2003;302(5647):1056- 1060.
23. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004;18(23):2867-2872.
24. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004;18(23):2861-2866.
25. Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry. 1993;14(5):472-477.
26. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNAand messenger RNAs that shuttle between polysomes and stress granules. J Biol Chem. 2006;281(39):29105-29119.
27. Chiu YL, Witkowska HE, Hall SC, et al. High-molecular- mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci U S A. 2006;103(42):15588-15593.
28. Gallois-Montbrun S, Kramer B, Swanson CM, et al. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol. 2007;81(5):2165-2178. (Pubitemid 46303334)
29. Wichroski MJ, Robb GB, Rana TM. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2006;2(5):e41.
30. Marin M, Golem S, Rose KM, Kozak SL, Kabat D. Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J Virol. 2008;82(2):987-998.
31. Gallois-Montbrun S, Holmes RK, Swanson CM, et al. Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol. 2008;82(11):5636-5642.
32. Niewiadomska AM, Tian C, Tan L, Wang T, Sarkis PT, Yu XF. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J Virol. 2007;81(17):9577-9583.
33. Goila-Gaur R, Khan MA, Miyagi E, et al. HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology. 2008;372(1):136-146.
34. Zhou Q, Yik JH. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev. 2006;70(3):646-659.
35. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell. 2006;23(3):297-305.
36. Dey A, Ellenberg J, Farina A, et al. bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition. Mol Cell Biol. 2000;20(17):6537-6549.
37. Farina A, Hattori M, Qin J, Nakatani Y, Minato N, Ozato K. Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol Cell Biol. 2004;24(20):9059-9069.
38. Yang Z, He N, Zhou Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell-cycle progression. Mol Cell Biol. 2008;28(3):967-976.
39. Mochizuki K, Nishiyama A, Jang MK, et al. The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase. J Biol Chem. 2008;283(14):9040-9048.
40. You J, Srinivasan V, Denis GV, et al. Kaposi's sarcoma- associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J Virol. 2006;80(18):8909-8919. (Pubitemid 44359965)
41. Schweiger MR, You J, Howley PM. Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. J Virol. 2006;80(9):4276-4285.
42. You J, Schweiger MR, Howley PM. Inhibition of E2 binding to Brd4 enhances viral genome loss and phenotypic reversion of bovine papillomavirus- transformed cells. J Virol. 2005;79(23):14956-14961.
43. You J, Croyle JL, Nishimura A, Ozato K, Howley PM. Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNAto host mitotic chromosomes. Cell. 2004;117(3):349-360.
44. Ottinger M, Christalla T, Nathan K, Brinkmannm M, Viejo-Borbolla A, Schulz TF. Kaposi's sarcoma-associated herpesvirus LANA-1 interacts with the short variant of BRD4 and releases cells from a BRD4- and BRD2/RING3-induced G1 cell-cycle arrest. J Virol. 2006;80(21):10772-10786.
45. Forte E, Luftig MA. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J Virol. 2009;83(6):2491-2499.
46. Chau CM, Deng Z, Kang H, Lieberman PM. Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp. J Virol. 2008;82(7):3428-3437.
47. Swiggard WJ, Baytop C, Yu JJ, et al. Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol. 2005;79(22):14179-14188.
48. Agosto LM, Yu JJ, Dai J, Kaletsky R, Monie D, O'Doherty U. HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology. 2007;368(1):60-72.
49. Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS. Vpr-induced cell-cycle arrest is conserved among primate lentiviruses. J Virol. 1996;70(4):2516-2524.